EA033007B1 - ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ - Google Patents
ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯInfo
- Publication number
- EA033007B1 EA033007B1 EA201590162A EA201590162A EA033007B1 EA 033007 B1 EA033007 B1 EA 033007B1 EA 201590162 A EA201590162 A EA 201590162A EA 201590162 A EA201590162 A EA 201590162A EA 033007 B1 EA033007 B1 EA 033007B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptide
- ospa
- lipidated
- heterodimer
- producing
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000012634 fragment Substances 0.000 title abstract 2
- 239000000833 heterodimer Substances 0.000 title abstract 2
- 108700006640 OspA Proteins 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 101710105714 Outer surface protein A Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000589968 Borrelia Species 0.000 abstract 1
- 206010061591 Borrelia infection Diseases 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668627P | 2012-07-06 | 2012-07-06 | |
| US13/802,991 US8986704B2 (en) | 2012-07-06 | 2013-03-14 | Mutant fragments of OspA and methods and uses relating thereto |
| PCT/EP2013/064403 WO2014006226A1 (en) | 2012-07-06 | 2013-07-08 | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201590162A1 EA201590162A1 (ru) | 2015-06-30 |
| EA033007B1 true EA033007B1 (ru) | 2019-08-30 |
Family
ID=49878705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590162A EA033007B1 (ru) | 2012-07-06 | 2013-07-08 | ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ |
| EA201991059A EA201991059A1 (ru) | 2012-07-06 | 2013-07-08 | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991059A EA201991059A1 (ru) | 2012-07-06 | 2013-07-08 | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ |
Country Status (24)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| BR112016015678B1 (pt) * | 2014-01-09 | 2024-02-06 | Valneva Austria Gmbh | Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica |
| KR102433588B1 (ko) * | 2014-06-27 | 2022-08-19 | 우베 가부시키가이샤 | 할로겐 치환 헤테로환 화합물의 염 |
| WO2016022958A2 (en) * | 2014-08-07 | 2016-02-11 | The Trustees Of Columbia University In The City Of New York | Tick-associated virus sequences and uses thereof |
| WO2017108902A1 (en) * | 2015-12-23 | 2017-06-29 | Novartis Ag | Oil-in-water emulsions including retinoic acid |
| US11345969B2 (en) | 2016-02-11 | 2022-05-31 | The Translational Genomics Research Institute | Systems and methods for the detection of infectious diseases |
| WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| KR20190001421U (ko) | 2019-05-26 | 2019-06-13 | 이준형 | 노크형 내부 수납식 칫솔 |
| CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
| CN111269919B (zh) * | 2020-03-19 | 2021-07-13 | 四川农业大学 | 玉米基因ZmLIP2及其应用 |
| CA3174666A1 (en) | 2020-04-09 | 2021-10-14 | Robert Schlegl | Improved methods of producing a lipidated protein |
| BR112022020438A2 (pt) * | 2020-04-09 | 2022-11-29 | Valneva Austria Gmbh | Composições compreendendo três proteínas de fusão ospa para uso médico |
| EP4395818A4 (en) * | 2021-09-02 | 2025-08-20 | Vaxcyte Inc | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE |
| WO2025015077A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens |
| WO2025015042A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008031133A2 (en) * | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| WO2011143617A1 (en) * | 2010-05-14 | 2011-11-17 | Baxter International Inc. | Chimeric ospa genes, proteins, and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) * | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| PT1311540E (pt) * | 2000-08-18 | 2008-03-20 | Univ New York State Res Found | Ospa de borrelia burgdorferi modificada |
| UA89481C2 (uk) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| SI2468300T1 (en) * | 2006-09-26 | 2018-03-30 | Infectios Disease Research Institute | A vaccine composition comprising a synthetic adjuvant |
| TWI376385B (en) | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
| US8466259B2 (en) | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
| EP2470664A4 (en) | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
| DK2753352T4 (da) | 2010-09-03 | 2022-09-12 | Valneva Austria Gmbh | Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| US9925257B2 (en) | 2011-09-23 | 2018-03-27 | Forsyth Dental Infirmary For Children | Vaccine and therapeutic delivery system |
| EP2788200B1 (en) | 2011-12-06 | 2018-07-04 | Mubea Carbo Tech GmbH | Wheel made out of fiber reinforced material and procedure to make an according wheel |
| PL3106176T3 (pl) | 2011-12-06 | 2018-03-30 | Valneva Austria Gmbh | Związki glinu do stosowania w terapeutykach i szczepionkach |
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| BR112016015678B1 (pt) | 2014-01-09 | 2024-02-06 | Valneva Austria Gmbh | Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| WO2017096486A1 (en) | 2015-12-10 | 2017-06-15 | National Research Council Of Canada | Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use |
| WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| WO2019092002A1 (en) | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| BR112021021637A2 (pt) | 2019-05-20 | 2021-12-21 | Valneva Se | Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório |
| JP7116256B1 (ja) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片 |
| CA3174666A1 (en) | 2020-04-09 | 2021-10-14 | Robert Schlegl | Improved methods of producing a lipidated protein |
-
2013
- 2013-03-14 US US13/802,991 patent/US8986704B2/en active Active
- 2013-07-08 TR TR2018/15419T patent/TR201815419T4/tr unknown
- 2013-07-08 DK DK13734430.5T patent/DK2869839T3/en active
- 2013-07-08 US US14/412,722 patent/US20150232517A1/en not_active Abandoned
- 2013-07-08 HU HUE13734430A patent/HUE041286T2/hu unknown
- 2013-07-08 EP EP18163951.9A patent/EP3360568B1/en active Active
- 2013-07-08 RS RS20181244A patent/RS57847B1/sr unknown
- 2013-07-08 JP JP2015519248A patent/JP6276258B2/ja active Active
- 2013-07-08 KR KR1020157001969A patent/KR102190981B1/ko active Active
- 2013-07-08 AU AU2013285364A patent/AU2013285364B2/en active Active
- 2013-07-08 NZ NZ73302613A patent/NZ733026A/en unknown
- 2013-07-08 ES ES13734430.5T patent/ES2688883T3/es active Active
- 2013-07-08 MX MX2015000013A patent/MX364623B/es active IP Right Grant
- 2013-07-08 EP EP20158277.2A patent/EP3689372A1/en active Pending
- 2013-07-08 CN CN201710809730.XA patent/CN107602676B/zh active Active
- 2013-07-08 MX MX2018014949A patent/MX391136B/es unknown
- 2013-07-08 EA EA201590162A patent/EA033007B1/ru unknown
- 2013-07-08 HR HRP20181689TT patent/HRP20181689T1/hr unknown
- 2013-07-08 EA EA201991059A patent/EA201991059A1/ru unknown
- 2013-07-08 ES ES18163951T patent/ES2800873T3/es active Active
- 2013-07-08 SI SI201331205T patent/SI2869839T1/sl unknown
- 2013-07-08 CN CN201380035702.7A patent/CN104487084B/zh active Active
- 2013-07-08 EP EP13734430.5A patent/EP2869839B1/en active Active
- 2013-07-08 NZ NZ703597A patent/NZ703597A/en unknown
- 2013-07-08 KR KR1020207035357A patent/KR102393038B1/ko active Active
- 2013-07-08 CA CA2876541A patent/CA2876541C/en active Active
- 2013-07-08 SM SM20180557T patent/SMT201800557T1/it unknown
- 2013-07-08 WO PCT/EP2013/064403 patent/WO2014006226A1/en not_active Ceased
- 2013-07-08 PL PL13734430T patent/PL2869839T3/pl unknown
- 2013-07-08 PT PT13734430T patent/PT2869839T/pt unknown
- 2013-07-08 LT LTEP13734430.5T patent/LT2869839T/lt unknown
-
2014
- 2014-12-15 ZA ZA2014/09222A patent/ZA201409222B/en unknown
-
2015
- 2015-02-17 US US14/623,681 patent/US20150250865A1/en not_active Abandoned
-
2016
- 2016-09-16 US US15/267,372 patent/US9926343B2/en active Active
- 2016-09-22 US US15/272,581 patent/US10544194B2/en active Active
-
2017
- 2017-08-22 AU AU2017218974A patent/AU2017218974C1/en active Active
-
2018
- 2018-02-27 US US15/906,618 patent/US11208439B2/en active Active
- 2018-10-18 CY CY181101073T patent/CY1120772T1/el unknown
-
2019
- 2019-12-04 US US16/702,885 patent/US11466058B2/en active Active
-
2021
- 2021-11-02 US US17/517,477 patent/US12195501B2/en active Active
-
2022
- 2022-09-14 US US17/932,226 patent/US20230295245A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008031133A2 (en) * | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| WO2011143617A1 (en) * | 2010-05-14 | 2011-11-17 | Baxter International Inc. | Chimeric ospa genes, proteins, and methods of use thereof |
Non-Patent Citations (6)
| Title |
|---|
| DEBORAH FASS: "Disulfide Bonding in Protein Biophysics", ANNUAL REVIEW OF BIOPHYSICS, ANNUAL REVIEWS, vol. 41, no. 1, 9 June 2012 (2012-06-09), pages 63 - 79, XP055080113, ISSN: 1936122X, DOI: 10.1146/annurev-biophys-050511-102321 * |
| DING, W. HUANG, X. YANG, X. DUNN, J.J. LUFT, B.J. KOIDE, S. LAWSON, C.L.: "Structural identification of a key protective B-cell epitope in lyme disease antigen OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 302, no. 5, 6 October 2000 (2000-10-06), United Kingdom, pages 1153 - 1164, XP004472344, ISSN: 0022-2836, DOI: 10.1006/jmbi.2000.4119 * |
| HERTADI, R. ; GRUSWITZ, F. ; SILVER, L. ; KOIDE, A. ; KOIDE, S. ; ARAKAWA, H. ; IKAI, A.: "Unfolding Mechanics of Multiple OspA Substructures Investigated with Single Molecule Force Spectroscopy", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 333, no. 5, 7 November 2003 (2003-11-07), United Kingdom, pages 993 - 1002, XP027101255, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2003.09.010 * |
| KOIDE, S. YANG, X. HUANG, X. DUNN, J.J. LUFT, B.J.: "Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 350, no. 2, 8 July 2005 (2005-07-08), United Kingdom, pages 290 - 299, XP004927295, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2005.04.066 * |
| LI H ET AL: "Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab.", NATIONAL ACADEMY OF SCIENCES, US, vol. 94, no. 8, 15 April 1997 (1997-04-15), US, pages 3584 - 3589, XP002456095, ISSN: 0027-8424, DOI: 10.1073/pnas.94.8.3584 * |
| VAN HOECKE, C. COMBERBACH, M. DE GRAVE, D. DESMONS, P. FU, D. HAUSER, P. LEBACQ, E. LOBET, Y. VOET, P.: "Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 17, 1 December 1996 (1996-12-01), AMSTERDAM, NL, pages 1620 - 1626, XP004016822, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(96)00146-6 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA033007B1 (ru) | ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ | |
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX2022005291A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| MX2015000338A (es) | Novedosa cepa de lactobacillus crispatus. | |
| IN2015KN00414A (cg-RX-API-DMAC7.html) | ||
| WO2010034032A3 (en) | Methods for preparing purified polypeptide compositions | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
| FI3564378T3 (fi) | Immunogeeninen koostumus | |
| IN2014DN06920A (cg-RX-API-DMAC7.html) | ||
| MX2019000346A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| GB201118201D0 (en) | Novel peptides | |
| MY193807A (en) | T-cell receptor and uses thereof | |
| MX357071B (es) | Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes. | |
| NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis | |
| NZ700467A (en) | Treatments suitable for malassezia infections | |
| NZ614255A (en) | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases | |
| WO2015054439A3 (en) | Hybrid factor viii polypeptides for use to treat hemophilia a | |
| WO2015048785A3 (en) | Mosaic conserved region hiv immunogenic polypeptides | |
| NZ707753A (en) | Purification of recombinant human galactocerebroside β-galactosidase (rhgalc) | |
| WO2013158818A3 (en) | Vaccines and methods to treat lyme disease in dogs | |
| PH12013501105A1 (en) | Tomm34 peptides and vaccines including the same | |
| GB201018125D0 (en) | Peptide | |
| MX2015006779A (es) | Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares. |